Radiotherapy of Head and Neck Cancer With SIB
Simultaneous Integrated Boost in the Primary and Adjuvant Therapy of Head and Neck Cancer: Quality Control Registry Prospective Longitudinal Obervation Trial
Wuerzburg University Hospital
750 participants
May 21, 2019
OBSERVATIONAL
Conditions
Summary
Title: Simultaneous Integrated Boost in Primary and Adjuvant Therapy of Head and Neck Tumors: Quality Control Registry Prospective Longitudinal Observational Study Short Title: Radiotherapy for Head and Neck Tumors with SIB Objective: To evaluate the efficacy and safety of definitive and adjuvant radio(chemo)therapy with simultaneous integrated boost (SIB) in patients with head and neck cancers. The study aims to assess local and regional control, overall survival, metastasis-free survival, therapy-related toxicities, and quality of life. Study Design: A prospective, longitudinal, non-interventional registry study documenting real-world outcomes and quality measures of therapy applied according to existing clinical guidelines.
Eligibility
Inclusion Criteria1
- Patients aged 18 and older with histologically confirmed malignant head and neck tumors, undergoing definitive or adjuvant radio(chemo)therapy at the University Hospital Würzburg
Exclusion Criteria3
- missing informed consent
- mental or physical disorders leading to inability to understand and/or fill the quationary
- judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06831903